AR101 powder provided in capsules & sachets for peanut hypersensitivity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Dec 2015: Trial registered, NCT02635776
  2. 22 Dec 2015: Trial started, NCT02635776

The trials

NCT02635776: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

State
Completed
Phase
Phase 3
People
555 taking part
Started
22 Dec 2015
Primary completion
21 Dec 2017
Arms
AR101 powder provided in capsules & sachets
Results
Posted on the registry
  1. 21 Dec 2015: Trial registered
  2. 22 Dec 2015: Trial started
  3. 2 Jul 2018: Trial completed
  4. 17 Mar 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.